Vienna, Austria, July 20, 2016 / B3C newswire / -- Hookipa Biotech AG, a company pioneering a new class of immunotherapies and vaccines, based on its proprietary viral vector platform Vaxwave®, today announces the start of a first-in-human study to …
Budapest, Hungary, July 18, 2016 / B3C newswire / - In 2016, HYD Pharma Inc. has been granted ethical approval by the State Institute for Drug Control (SIDC) in Slovakia for Phase 2 as one-of-the-first clinical trials to prove the anticancer effect of …
Ravensburg, Germany, July 15, 2016 / B3C newswire / -- At a meeting held on July 12 for interested residents and other stakeholders, officials of the City of Des Plaines and Vetter were given the opportunity to share initial plans for the proposed purchase …
Tel-Aviv, Israel, July 13, 2016 / B3C newswire / -- RedHill Biopharma Ltd. (NASDAQ: RDHL) (TASE: RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, …
Mainz, Germany, July 12, 2016 / B3C newswire / -- BioNTech Diagnostics GmbH announces the publication of new study data which confirms the high analytical performance of the in vitro diagnostic test kit MammaTyper® (CE labeled IVD) in breast cancer …
July 11, 2016 / B3C newswire / -- An international project to develop a large, globally accessible, bank of new cancer cell culture models for the research community launches today (Monday). The National Cancer Institute (NCI), Cancer Research UK, the …
Melbourne, Australia, July 8, 2016 / B3C newswire / -- AdAlta Limited, the biotechnology company specialising in the discovery and development of protein based therapeutics is seeking to raise up to AU$10 million in an initial public offering (IPO) on the …
Goettingen, Germany, July 7, 2016 / B3C newswire / -- Preparing samples by clarification is an essential step prior to nearly all analytical techniques, such as high pressure liquid chromatography (HPLC). This filtration step to eliminate particles is …
In-depth profiling of IgG glycosylation coupled with ADCC assays enables generation of robust biosimilar comparability data Glasgow, UK, July 7, 2016 / B3C newswire / -- Sartorius Stedim Biotech (SSB), a leading international supplier for the …
RedHill and its co-development partner, IntelGenx, have signed a definitive agreement with Grupo JUSTE granting an exclusive license to commercialize their acute migraine drug RIZAPORT™ in Spain, and a right of first refusal for additional territories …
Tübingen, Germany, July 5, 2016 / B3C newswire / -- Atriva Therapeutics GmbH announces the acquisition of the co-infection patent (Application Nr: PCT/IB2015/053644) from the University of Muenster, Germany. This patent covers the beneficial and …
Utrecht, The Netherlands, June 30, 2016 / B3C newswire / -- The EUROSTARS grant of EUR 1.5 million is awarded to a multidisciplinary consortium including SomantiX BV, PharmBioTec GmbH and Pharmacelsus GmbH. EUROSTARS is a joint program between EUREKA and …
Conclusion of randomized, double-blinded study expected by end of 2016 Joint laboratory for biomarker research in peritoneal dialysis established with Medical University of Vienna Vienna, Austria, June 30, 2016 / B3C newswire / -- Zytoprotec, a …
Data presented as invited oral presentation at 10th International Symposium on Pneumococci & Pneumococcal Diseases Antibody responses to ubiquitous antigens across strains shown, indicative of broad protection Statistically significant increases in …
Positive results in a double-blind controlled study in the knee Krems an der Donau, Austria, June 29, 2016 / B3C newswire / -- OrthoSera GmbH, an orthobiologics company developing serum-based solutions for musculoskeletal indications announces that a …
Additional non-dilutive funds to accelerate US market approval and product launch Support aims to increase familiarity/acceptance in US burn centers, demonstrate economic benefits and increase acceptance of ReCell® in US Burns Centers Funds will be …
The peer-reviewed article, authored by scientists from the University of Central Florida, concludes that the triple combination of the RHB-104 active components provides excellent synergistic activity in the inhibition of mycobacterial growth, potentially …
Munich, Germany, June 22, 2016 / B3C newswire / -- Morphochem, a private clinical-stage pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) Application for the company’s …
Final results from the Phase I study with YELIVA™ (ABC294640) in patients with advanced solid tumors confirmed that the study, conducted at the Medical University of South Carolina (MUSC), successfully met its primary and secondary endpoints, demonstrating …
The first patients have been dosed in the randomized, double-blind, placebo-controlled Phase II study with BEKINDA™ 12 mg for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D) in 120 subjects in 12 clinical sites in the U.S. IBS is one …
